Efficacy and Safety of Ziftomenib Combined with Venetoclax and Azacitidine in Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia
Highlight
– Ziftomenib, an oral menin inhibitor, combined with venetoclax and azacitidine shows promising efficacy in relapsed/refractory NPM1-mutated AML patients.
– Composite complete remission (CRc) reached 46% overall, with higher rates in venetoclax-naïve patients (70%).
– The combination therapy was generally well tolerated with manageable adverse events including hematologic toxicities and rare differentiation syndrome.
– Median duration of response was 8.6 months, and median overall survival was not reached, suggesting durable responses.
Study Background
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.